Description

Cyclopentanepropanoic acid, α-[(formylhydroxyamino)methyl]-, 2-[5-fluoro-6-[(9aS)-hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-2-methyl-4-pyrimidinyl]hydrazide, (αR)- is a high-purity, advanced pharmaceutical intermediate with a complex heterocyclic structure. This compound is critical for research and development in medicinal chemistry, particularly in the synthesis of novel therapeutic agents targeting specific biological pathways. It is primarily utilized by pharmaceutical R&D laboratories and fine chemical manufacturers engaged in the production of active pharmaceutical ingredients (APIs) for clinical trials and commercial manufacturing.

Application

• Pharmaceutical Intermediate: Serves as a key building block in the synthesis of novel drug candidates, particularly in oncology and central nervous system (CNS) therapeutic areas.
• Medicinal Chemistry Research: Used in structure-activity relationship (SAR) studies and lead optimization processes to develop new chemical entities.
• Active Pharmaceutical Ingredient (API) Development: Employed in the pilot-scale and commercial-scale synthesis of complex target molecules for clinical and commercial use.
• Contract Research & Manufacturing (CRAM): Supplied to organizations specializing in custom synthesis and process development for the pharmaceutical industry.
• Biochemical Research: May be used as a tool compound or precursor in biochemical assays to study enzyme inhibition or receptor binding.

Basic Information

Product Name	Cyclopentanepropanoic acid, α-[(formylhydroxyamino)methyl]-, 2-[5-fluoro-6-[(9aS)-hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-2-methyl-4-pyrimidinyl]hydrazide, (αR)-
CAS No.	1152107-25-9
Molecular Formula	Contact for details
Molecular Weight	Contact for details
Synonyms	(αR)-2-[5-Fluoro-6-[(9aS)-octahydropyrazino[2,1-c][1,4]oxazin-8-yl]-2-methyl-4-pyrimidinyl]hydrazide of α-[(formylhydroxyamino)methyl]cyclopentanepropanoic acid; (R)-enantiomer of the specified hydrazide; Advanced Fluorinated Pyrimidine Derivative; Hexahydropyrazino-oxazine based Intermediate; Pharmaceutical Building Block 1152107-25-9.
EINECS	Contact for details

Quality Control

This high-value intermediate is manufactured under strict quality control protocols to ensure batch-to-batch consistency and purity suitable for pharmaceutical applications. Production adheres to cGMP (current Good Manufacturing Practice) guidelines where applicable. Comprehensive analytical testing, including HPLC, NMR, and MS, is performed to verify identity, purity, and the absence of critical impurities. A detailed Certificate of Analysis (COA) is provided with each shipment, documenting all relevant specifications.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (15-25°C). This product is hygroscopic (moisture-sensitive) and should be handled under an inert atmosphere (e.g., nitrogen or argon) when opening to prevent moisture uptake and potential oxidation. Keep the container tightly sealed when not in use.

Specification

Item	Specification
Appearance	White to off-white solid
Identification (HPLC)	Conforms
Identification (NMR)	Conforms
Purity (HPLC)	≥ 98.0%
Water Content (KF)	≤ 0.5%
Residue on Ignition	≤ 0.1%
Heavy Metals	≤ 10 ppm
Single Unknown Impurity	≤ 0.5%
Total Impurities	≤ 2.0%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.